Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...

Bibliográfalaš dieđut
Váldodahkkit:	Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	BMJ Publishing Group 2022

Geahča maid

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
Dahkki: Josef S Smolen, et al.
Almmustuhtton: (2022-11-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

Ixekizumab in the treatment of psoriatic arthritis
Dahkki: Yu. L. Korsakova, et al.
Almmustuhtton: (2024-12-01)

Methotrexate in psoriasis and psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
Dahkki: Coates, LC, et al.
Almmustuhtton: (2016)

Measuring outcomes in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2020)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
Dahkki: Weinstein, SM, et al.
Almmustuhtton: (2021)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Dahkki: Kavanaugh, A, et al.
Almmustuhtton: (2024)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
Dahkki: Miller J, et al.
Almmustuhtton: (2021-12-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Dahkki: Bruce W. Kirkham, et al.
Almmustuhtton: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
Dahkki: P.S. Helliwell
Almmustuhtton: (2011-09-01)

Psoriatic arthritis
Dahkki: FitzGerald, O, et al.
Almmustuhtton: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

What should be the primary target of "treat to target" in psoriatic arthritis?
Dahkki: Coates, LC, et al.
Almmustuhtton: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2022)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2018)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Dahkki: April W. Armstrong, et al.
Almmustuhtton: (2024-05-01)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Dahkki: Atul Deodhar, et al.
Almmustuhtton: (2023-08-01)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
Dahkki: Ye, W, et al.
Almmustuhtton: (2021)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2020)

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
Dahkki: Coates, LC, et al.
Almmustuhtton: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
Dahkki: Mease, P, et al.
Almmustuhtton: (2017)

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Dahkki: April W. Armstrong, et al.
Almmustuhtton: (2024-07-01)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
Dahkki: Orbai, A-M, et al.
Almmustuhtton: (2019)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
Dahkki: A. M. Dadalova, et al.
Almmustuhtton: (2020-11-01)

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab
Dahkki: A. Egeberg, et al.
Almmustuhtton: (2022-07-01)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
Dahkki: Ye, W, et al.
Almmustuhtton: (2021)

Current concepts and unmet needs in psoriatic arthritis
Dahkki: Mahmood, F, et al.
Almmustuhtton: (2017)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2024)

Psoriatic arthritis: prospects for the future
Dahkki: Hackett, S, et al.
Almmustuhtton: (2022)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Dahkki: Yazji, SM, et al.
Almmustuhtton: (2025)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
Dahkki: Leung, Y-Y, et al.
Almmustuhtton: (2023)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2021)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
Dahkki: Coates, LC, et al.
Almmustuhtton: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Dahkki: Coates, L, et al.
Almmustuhtton: (2016)